Comparative Pharmacology
Head-to-head clinical analysis: INGREZZA versus XENAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INGREZZA versus XENAZINE.
INGREZZA vs XENAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vesicular monoamine transporter 2 (VMAT2) inhibitor; reduces presynaptic dopamine release.
Deutetrabenazine selectively and reversibly inhibits vesicular monoamine transporter 2 (VMAT2), thereby reducing dopamine and monoamine storage and release in presynaptic neurons.
80 mg orally once daily; may titrate from 40 mg once daily for 7 days to reduce nausea.
12.5 mg orally twice daily initially; titrate slowly by 12.5 mg every 3-5 days up to 50 mg twice daily (total daily dose 100 mg). Maximum recommended total daily dose: 100 mg.
None Documented
None Documented
Terminal elimination half-life of deutetrabenazine is 9-10 hours; clinical context: supports twice-daily dosing.
7-16 hours (mean 9-12 hours); requires twice-daily dosing for steady-state control of chorea.
Approximately 60% renal (as unchanged drug and metabolites) and 30% fecal.
Primarily renal (75-85% as metabolites, <2% unchanged); minimal biliary/fecal elimination.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor